AnaptysBio (NASDAQ:ANAB - Get Free Report) had its price target raised by stock analysts at JPMorgan Chase & Co. from $36.00 to $42.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 157.04% from the stock's previous close.
ANAB has been the subject of a number of other reports. HC Wainwright reiterated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. Guggenheim cut their price objective on AnaptysBio from $90.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, December 12th. Wedbush reiterated an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. BTIG Research cut AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Finally, Truist Financial cut their price objective on AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a report on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, AnaptysBio currently has an average rating of "Moderate Buy" and a consensus price target of $35.11.
View Our Latest Stock Report on AnaptysBio
AnaptysBio Trading Down 0.4 %
Shares of NASDAQ ANAB traded down $0.06 during mid-day trading on Wednesday, hitting $16.34. The company had a trading volume of 593,252 shares, compared to its average volume of 1,048,744. The company has a market capitalization of $501.10 million, a price-to-earnings ratio of -2.69 and a beta of 0.02. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The stock's 50-day moving average price is $16.23 and its 200-day moving average price is $23.99.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. As a group, equities research analysts forecast that AnaptysBio will post -6.08 earnings per share for the current year.
Insider Activity at AnaptysBio
In related news, Director Ecor1 Capital, Llc bought 65,184 shares of the company's stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the acquisition, the director now directly owns 7,860,180 shares of the company's stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.70% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On AnaptysBio
Several institutional investors and hedge funds have recently bought and sold shares of ANAB. GSA Capital Partners LLP purchased a new stake in AnaptysBio in the 3rd quarter worth approximately $574,000. Victory Capital Management Inc. lifted its holdings in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock worth $7,948,000 after buying an additional 206,750 shares during the period. Jennison Associates LLC purchased a new stake in AnaptysBio in the 3rd quarter worth approximately $8,874,000. Intech Investment Management LLC purchased a new stake in AnaptysBio in the 3rd quarter worth approximately $229,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in AnaptysBio by 3.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,321 shares of the biotechnology company's stock worth $5,371,000 after buying an additional 5,043 shares during the period.
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
See Also
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
